-
Fierce Biotech3 months ago
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali...
-
STAT News – Biotech3 months agoHer son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey
Her son had been sick for four months when Blanca Morales started asking about a transplant. It had started with a case of strep throat from...
-
STAT News – Biotech3 months agoOpinion: The AI push in health care is deepening medicine’s trust crisis
After OpenAI and Anthropic launched dedicated health care initiatives in January, a study published in February found that OpenAI’s ChatGPT Health had a 50% error rate, incorrectly recommending that care be delayed in emergency test cases...
-
Fierce Biotech3 months ago
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the...
-
GEN – Genetic Engineering & Biotechnology News3 months ago
StockWatch: CytomX Shares Yo-Yo on Colorectal Cancer Data
CytomX Therapeutics (NASDAQ: CTMX) drew attention a few days ago after its six-year-old, up-to-$1.68 billion cancer collaboration with Astellas Pharma (Tokyo: 4503) was terminated by the...
-
Nature – Synthetic Biology3 months ago
Engineering ligands for theophylline riboswitches expands its regulatory dynamic range in prokaryotic and eukaryotic systems
Post Content
-
Nature – Synthetic Biology3 months ago
Analysis of heterocycle formation and stereochemical control by a non-ribosomal peptide synthetase condensation domain
Post Content
-
GEN – Genetic Engineering & Biotechnology News3 months ago
Novartis Acquires Pikavation for up to $3B, Expanding Cancer Pipeline
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor programs designed...
-
Fierce Biotech3 months ago
NIH grant cuts hit women, early-career scientists the hardest: analysis
Last year’s funding cuts at the National Institutes of Health disproportionately impacted women and early-career researchers, according to a new analysis, raising questions about what the...
-
ScienceDaily – Biotechnology3 months ago
Hidden antibiotics in river fish spark new food safety fears
Antibiotics are accumulating in a major Brazilian river, especially during the dry season when pollution becomes more concentrated. Scientists even detected a banned drug inside fish...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
